1. miR-218-5p inhibits the malignant progression of glioma via targeting TCF12
- Author
-
Guomin Rao, Ling Cheng, Jingshun Gu, Dongchun Wang, Xiaotang Wu, Kun Zhang, Juntong Wang, Aiwu You, Xuehua Ge, Yuyan Zhang, Mengjiao Zhu, Xuan Liu, and Jun Li
- Subjects
0301 basic medicine ,Cancer Research ,Cell ,Regulator ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Western blot ,Cell Movement ,Cell Line, Tumor ,Glioma ,Basic Helix-Loop-Helix Transcription Factors ,medicine ,Humans ,Neoplasm Invasiveness ,Luciferase ,Transcription factor ,Cell Proliferation ,medicine.diagnostic_test ,General Medicine ,medicine.disease ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Apoptosis ,030220 oncology & carcinogenesis ,Cancer research - Abstract
Several studies have shown the ability of transcription factor 12 (TCF12) to promote tumor malignant progression, but its function in glioma cells has not been fully elucidated. In this study, we analyzed the data from TCGA by bioinformatics and found that in glioma tissue, TCF12 was conspicuously highly expressed while miR-218-5p was significantly low-expressed. The downregulation of miR-218-5p was correlated with adverse prognosis in patients with glioma. miR-218-5p was found to be negatively associated with TCF12 by Pearson correlation analysis, and dual luciferase assay was employed to verify that miR-218-5p and TCF12 had a targeting relationship. qRT-PCR and Western blot assays were used to verify that the expression of TCF12 was regulated by its upstream regulator miR-218-5p. Moreover, cell experiments validated that overexpressed TCF12 could promote the proliferation, migration, and invasion of glioma cells and inhibit their apoptosis, whereas overexpressing miR-218-5p at the same time could reverse this phenomenon. Our study demonstrates the regulatory mechanism of the miR-218-5p/TCF12 axis in gliomas, which lays a foundation for searching for new therapeutic approaches for glioma.
- Published
- 2021